Skip to search formSkip to main contentSkip to account menu

CC-486

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oral Azacitidine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute…
Introduction: Many older patients (pts) with AML respond to intensive induction chemotherapy (IC), but responses are often short… 
2019
2019
A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors
Epigenetic abnormalities are manifold in all solid tumors and include changes in chromatin configuration and DNA methylation. The… 
2019
2019
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)
Abstract In preclinical studies, oral azacitidine (CC-486), a hypomethylating agent, has been shown to have a direct anti-MM… 
2018
2018
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Purpose: This large two-part, three-arm phase I study examined the safety and tolerability of CC-486 (an oral formulation of… 
2016
2016
CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies
Background: Injectable HMAs (azacitidine [AZA], decitabine) are the standard of care in higher-risk myelodysplastic syndromes (HR… 
Highly Cited
2015
Highly Cited
2015
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA methyltransferase inhibitor in clinical… 
Review
2015
Review
2015
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
The myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid malignancies characterized by multilineage… 
2015
2015
CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML)
Background: When administered subcutaneously (SC), the epigenetic modifier, azacitidine (AZA) is shown to improve overall… 
2014
2014
Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies
Parenteral azacitidine improves overall survival in higher‐risk myelodysplastic syndromes. An oral azacitidine formulation would… 
2012
2012
Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes
Abstract 424 Background: Azacitidine for injection has been shown to prolong overall survival in patients (pts) with higher-risk… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)